La Jolla Pharmaceutical preclinical data

In a mouse model of NASH, oral LJPC-1010 significantly reduced non-alcoholic fatty liver disease (NAFLD) activity score vs. vehicle-treated controls (p<0.001). Additionally, LJPC-1010 led to a reducti...